Breast and Lung Cancers are global problems. In the U.S. nearly one in eight women will develop Breast Cancer in their lifetime. Lung cancer is the leading cancer killer worldwide. Importantly, there is also an unmet need for targeted therapy for highly aggressive triple negative Breast Cancer as well as for non-small cell and small cell lung cancers. JAA-F11 can meet these needs targeting 88% of all Breast Cancer (competitor Herceptin targets only 25% with Her-2) and 84% of lung cancers.
Our technology will treat primary and metastatic cancer by directly killing cancer cells. In addition, JAA-F11 along with direct killing has long term potential to block metastasis extending patient survival. JAA-F11 is expected to be safe as humans have small amounts of naturally occurring antibody to the TF-Ag. Recent in vivo efficacy studies show potential for lung cancer as well.
De-risking and validation through the non-dilutive partnership with the NCI Experimental Therapeutics (NExT) program provides For-Robin with resources to bring hJAA-F11 through the FDA IND to first in human clinical trials, by Spring 2021.
For-Robin is seeking partner(s) and investors to support 1) extended Phase I clinical trials in lung and breast cancer therapy with humanized JAA-F11 antibody (hJAA-F11) and/or 2) clinical trials of differential imaging diagnostic applications of hJAA-F11 in lung cancer.
Currently funded by 1 R43 CA236023-01A1 (4/1/19-3/31/21) JAA-F11 Anti-Thomsen-Friedenreich Antigen Targeted Imaging for Lung Cancer Differential Diagnosis Total non-dilutive funding $6,827,000 raised to date: $2,827,000, grants and value of NEXT partnering about $4,000,000.